Table 1

Demographic and clinical characteristics of the OAB cohort at baseline,Truven MarketScan databases 2007–2015

 OverallBy ageBy baseline anticholinergic burden*By sex
<65≥65No burdenSome burdenMaleFemale
n=154 432n=117 271n=37 161n=54 602n=99 830n=49 597n=104 835
n%n%n%n%n%n%n%
Age (years)
Mean (SD)55.715.249.411.075.77.551.414.658.115.056.214.055.515.8
Median (IQR)5646–645243–587569–815242–605849–685748–645546–64
≤4536 03923.336 03930.70017 30031.718 73918.899152026 12424.9
46–5539 78425.839 78433.90015 35728.124 42724.512 74325.727 04125.8
56–6543 41428.141 44835.319665.314 61026.828 80428.916 16032.627 25426
66–7517 64911.40017 64947.54383813 26613.3611512.311 53411
76–8513 0998.50013 09935.223414.310 75810.837657.693348.9
86+44472.9004447126111.138363.88991.835483.4
Female sex 104 83567.979 15967.525 67669.129 99954.974 83675.000104 835100.0
Comorbidities†
Hypertension, uncomplicated55 90036.235 33230.120 56855.314 40126.441 49941.619 89540.136 00534.3
Diabetes mellitus and diabetic peripheral neuropathy21 49013.913 42411.4806621.7554010.115 95016.0820516.513 28512.7
Cerebrovascular disease and stroke85175.531802.7533714.415992.969186.929055.956125.4
Dizziness83985.453664.630328.219053.564936.522494.561495.9
Osteoporosis66094.331622.734479.316263.049835.04710.961385.9
Arthritis63454.143703.719755.312952.450505.110972.252485.0
Falls or fractures within the preceding year 55423.630592.624836.711632.143794.412102.443324.1
Lifestyle factors
Smoking13 5488.888367.5471212.729565.410 59210.644268.991228.7
Alcohol abuse7680.56580.61100.31880.35800.63740.83940.4
Medications
Opioids56 03636.341 60835.514 42838.811 04420.244 99245.114 88730.041 14939.3
Benzodiazepine use27 50717.820 25217.3725519.523494.325 15825.2588211.921 62520.6
Chronic use of inhaled or oral corticosteroids53673.533062.820615.58881.644794.514923.038753.7
Risk factors for high anticholinergic burden
Depression, neurotic disorders or psychosis32 67421.227 03723.1563715.2783814.424 83624.9813516.424 53923.4
Chronic obstructive pulmonary disease10 0166.556044.8441211.918243.381928.231676.468496.5
Parkinson’s disease/other neurological impairments59733.934012.925726.910591.949144.918473.741263.9
Dementia15701.01380.114323.92160.413541.44080.811621.1
Intestinal motility disorders1520.11070.1450.1430.11090.1390.11130.1
Elixhauser score, mean (SD) 13.913.335.013.014.313.913.9
Timing of OAB
Incident case1 06 73069.184 88872.421 84258.843 68880.063 04263.136 78374.269 94766.7
Prevalent case47 70230.932 38327.615 31941.210 91420.036 78836.912 81425.834 88833.3
Anticholinergic burden
Mean (SD)266.7486.5213.8443.9433.8570.300412.6553.2154.2365.3320.0526.1
Median (IQR)300.0, 314.0130.0, 200.01833.0, 713.000.0, 0.018036.0, 609.010.0, 120.060.00.0, 445.5
No burden54 60235.446 74639.9785621.154 602100.00024 60349.629 99928.6
Low38 66925.031 22926.6744020.00038 66938.711 50423.227 16525.9
Medium31 71920.522 00618.8971326.10031 71931.8846017.123 25922.2
High29 44219.117 29014.712 15232.70029 44229.5503010.124 41223.3
  • *Baseline anticholinergic burden assessed over the 12-month pre-index period.

  • †Only comorbidities identified among >2.5% are presented. The following were identified among <2.5% of the cohort: syncope, complicated hypertension, cognitive impairment, Alzheimer’s disease, musculoskeletal problems, hyperparathyroidism, decreased vision, chronic kidney disease, leg and foot amputation, hypotension, and palmonental reflex.

  • OAB, overactive bladder.